NVS
No price yet
Announcements
Nothing here yet
Daily updates
- Novartis licensed worldwide rights to Abogen Biosciences' ABO2203, an mRNA-based CD19/CD3 T-cell engager for autoimmune diseases, in a deal worth more than $7.5 billion including a $575 million upfront payment. The therapy is designed to reset B cells and potentially suppress disease-driving immune responses.Oct 4, 2026
- Novartis halted eight CAR-T rap-cel trials in autoimmune diseasesSep 7, 2026
- Remibrutinib Phase 3 results were positive in multiple sclerosis while rap-cel trials were haltedSep 1, 2026
FDA designations
Nothing here yet
News
- Novartis discontinues efforts to develop Fabhalta for lupus nephritis following a failed Phase 2 trialOct 19, 2026
- Novartis expands the U.S. label for its oral BTK inhibitor Rhapsido to include a second indication for chronic hivesOct 8, 2026
- Novartis commits nearly $8 billion to a Chinese biotech's RNA drug platformOct 6, 2026
- Novartis adds an Abogen Biosciences T-cell engager for autoimmune diseases to its pipeline in a deal potentially worth more than $7.5 billionOct 4, 2026
- Novartis halted eight CAR-T rap-cel trials in autoimmune diseases after three deaths, while BMS also paused zola-cel studies as a precautionSep 7, 2026